Annexon Biosciences

Founded in 2011, we are a clinical-stage biopharmaceutical company. We develop a new class of complement medicines for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Our pipeline targets diseases caused by the abnormal activation of C1q, which starts the classical complement pathway.

Our product candidates include ANX005 (intravenous), ANX007 (intravitreal), and ANX009 (subcutaneous). All are designed to block C1q activity and the entire classical complement pathway. We use a biomarker-driven approach in our development process.

Our story began in 2007 when Dr. Ben Barres discovered C1q’s role in neurodegenerative disorders. He co-founded our company with Dr. Arnon Rosenthal, who helped develop ANX005.

By 2014, we secured Series A financing and developed ANX005 and other classical pathway inhibitors. In 2016, we demonstrated how important it is to inhibit C1q at the top of the pathway.

ANX005 reached clinical proof-of-concept in Guillain-Barré Syndrome (GBS) in 2017. In 2019, ANX007 showed target engagement in the eye with intravitreal administration in glaucoma patients. Our IPO in 2020 helped us expand our pipeline and organization. In 2021, ANX009 showed target engagement in the blood after subcutaneous administration in healthy volunteers.

By 2023, ANX005 completed enrollment in its first Phase 3 GBS program and received Orphan Drug Designation from the EMA. ANX007 also showed dose-dependent preservation of visual function in a Phase 2 trial for geographic atrophy (GA) patients, and ANX1502 reached target pharmacokinetics in a Phase 1 healthy volunteer study.

Our mission is to bring therapies to patients with complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.

Our values are:

• Warrior Spirit: We strive for excellence, are courageous, act with urgency, and persevere to win.
• Sound Judgment: We apply our wisdom, focus on what’s important, test our ideas, address root causes, and keep things simple.
• Passion: We are innovative, dedicated, and constantly learning. We remember our work impacts patients and their families.
• All for One: We believe our collective effort is stronger than individual parts. We are great team players, treat others with respect, and are humble and trustworthy.
• Thrive!: We encourage fun, optimism, and celebrating successes, large and small. We enjoy the journey.

We are a team of 51-200 employees. Our culture encourages everyone to bring their best to a team-based environment and to follow the science. We want every team member to contribute and thrive. Our team is experienced, collaborative, and driven. Our Scientific Co-Founder, Dr. Ben Barres, was instrumental in our early scientific direction.

We offer a competitive base salary and equity, including an employee stock purchase plan. Our comprehensive health benefits package covers medical, dental, and vision, along with a 401(k) plan and flexible spending options.

We support work-life balance through flexible work schedules and remote opportunities. For our Brisbane, CA office, we provide shuttle service from BART, CalTrain, and the Ferry. We are an equal opportunity employer.